Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG (TiCAB)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Deutsches Herzzentrum Muenchen
Information provided by (Responsible Party):
Deutsches Herzzentrum Muenchen Identifier:
First received: December 19, 2012
Last updated: May 7, 2014
Last verified: May 2014

This study (TiCAB) is designed as a pivotal efficacy and safety study of Ticagrelor in patients undergoing coronary artery bypass operation. It is designed for the prevention of fatal and non-fatal cardiovascular events in this patient population, a significant, yet unmet medical need.

Condition Intervention Phase
Coronary Artery Desease,
Stable Angina,
Acute Coronary Syndrome
Drug: Ticagrelor
Drug: Aspirin
Drug: Placebo - Ticagrelor
Drug: Placebo - Aspirin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG

Resource links provided by NLM:

Further study details as provided by Deutsches Herzzentrum Muenchen:

Primary Outcome Measures:
  • MACCE [ Time Frame: at 12 months after coronary artery bypass surgery ] [ Designated as safety issue: No ]
    Composite of cardiovascular death, myocardial infarction, target vessel revascularization, and stroke

Secondary Outcome Measures:
  • Cardiovascular death [ Time Frame: at 12 months after coronary artery bypass surgery ] [ Designated as safety issue: No ]
  • Major bleeding events [ Time Frame: within 12 months after coronary arerty bypass surgery ] [ Designated as safety issue: Yes ]
    Incidence of major bleeding events

  • All cause death [ Time Frame: at 12 months after coronary artery bypass surgery ] [ Designated as safety issue: No ]
    All cause death

  • Myocardial Infarction [ Time Frame: at 12 months after coronary artery bypass surgery ] [ Designated as safety issue: No ]
  • Target Lesion Revascularization [ Time Frame: at 12 months after coronary artery bypass surgery ] [ Designated as safety issue: No ]
  • Stroke [ Time Frame: at 12 months after coronary artery bypass surgery ] [ Designated as safety issue: No ]

Estimated Enrollment: 4008
Study Start Date: April 2013
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ticagrelor
Intervention: Drug: Ticagrelor verum + Aspirin placebo
Drug: Ticagrelor
90mg twice daily dose
Other Name: Brilique
Drug: Placebo - Aspirin
Other Name: Placebo
Active Comparator: Aspirin
Intervention: Drug: Aspirin verum + Ticagrelor placebo
Drug: Aspirin
Aspirin 100mg once daily
Other Name: ASS
Drug: Placebo - Ticagrelor
Other Name: Placebo

Detailed Description:

For stable patients who underwent coronary bypass operation, Aspirin alone currently represents the gold standard of antiplatelet treatment. A few smaller studies using a combination therapy of antiplatelet drugs including Aspirin and Clopidogrel have shown conflicting results. Albeit a number of cardiac surgeons prefer dual antiplatelet therapy with Aspirin and Clopidogrel, Aspirin monotherapy is currently the only guideline recommended therapy after CABG.

A sub-analysis of PLATO trial comprising more than 1200 ACS patients who were not considered to be appropriately suited for PCI and therefore subjected to CABG operation demonstrated an impressive reduction in mortality in those patients treated with Ticagrelor and Aspirin as compared to Clopidogrel and Aspirin. The labelling of Ticagrelor says that the drug should be paused 7 days prior to surgery. However, a further analysis of this substudy revealed that the largest benefit in the Ticagrelor + Aspirin group as compared to the Clopidogrel + Aspirin group was found in those who stopped study medication at about 48 - 72 hours prior to surgery. There have been pharmacological studies that showed that Ticagrelor may precondition the heart for the trauma of surgery via adenosine mediated effects. Thus, the enormous benefit in the Ticagrelor arm of the PLATO study may be secondary to a pleiotropic action. There was no indication of an accelerated bleeding risk in this study and pharmacological studies document that platelet function should be largely restored of a pause of 48 - 72 hours, such that this duration may allow the optimal preparation for CABG surgery.

Based on the unmet clinical need regarding optimal antiplatelet therapy after CABG, the results of the PLATO CABG substudy and the observation that Ticagrelor benefits increase with decreasing Aspirin doses, Ticagrelormonotherapy (2x 90mg/day) appears to offer the best balance of safety with anticipated improved efficacy over Aspirin alone. However, there are no data available to support this hypothesis.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients 18 years of age or older
  2. Informed, written consent by the patient
  3. Indication for CABG surgery:

    • coronary three vessel disease, or
    • left main stenosis, or
    • two vessel disease with impaired left ventricular function

Exclusion Criteria:

  1. Indication for oral anticoagulation therapy (i.e. AF) at the time of randomization
  2. Cardiogenic shock, haemodynamic instability
  3. Acute myocardial infarction at presentation (STEMI)
  4. Need for urgent revascularization within 5 days from presentation
  5. Single or two vessel disease with normal LV function (≥ 50%)
  6. Need for concomitant non-coronary surgery (e.g. valve replacement)
  7. Contraindication for Aspirin or Ticagrelor use (i.e. known allergy)
  8. History of bleeding diathesis within three months prior presentation, significant GI bleed, intra cranial hemorrhage, or liver failure
  9. Patient requires dialysis
  10. Known, clinically important thrombocytopenia (i.e. <100.000/µl)
  11. Known, clinically important anaemia (i.e. <10mg/dl)
  12. Participation in another investigational drug or device study in the last 30 days
  13. Pregnancy or lactation (for premenopausal women 2 methods of reliable contraception, one of which must be barrier method, are required)
  14. Concomitant oral or intravenous therapy (see examples below) with strong CYP3A inhibitors, CYP3A substrates with narrow therapeutic indices, or strong CYP3A inducers which cannot be stopped for the course of the study

    • Strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir, over 1 litre daily of grapefruit juice.
    • Substrates with narrow therapeutic index: cyclosporine, quinidine.
    • Strong inducers: rifampin/rifampicin, phenytoin, carbamazepine.
  15. Any other condition such as active cancer
  16. Life expectancy less than 12 months that may result in protocol non-compliance or a risk for being lost to follow-up
  17. Indication for major surgery (e.g. cancer treatment, carotid surgery, cerebral surgery, major vascular surgery)
  18. Previous enrolment or randomization of treatment in the present study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01755520

Contact: Heribert Schunkert, MD 00498912184073
Contact: Gisela Schoemig 00498912181547

Medizinische Universität Wien Recruiting
Vienna, Austria, 1090
Contact: Sigrid Sandner, MD    +43-140400 ext 6969   
Principal Investigator: Sigird Sandner, MD         
Deutsches Herzzentrum München Recruiting
Munich, Bavaria, Germany, 80636
Contact: Heribert Schunkert, MD    00498912184073   
Contact: Adnan Kastrati, MD    00498912184578   
Principal Investigator: Heribert Schunkert, MD         
Universitätsklinikum Aachen Not yet recruiting
Aachen, Germany, 52074
Contact: Rüdiger Autschbach, MD    +49-241-80 ext 89221   
Principal Investigator: Rüdiger Autschbach, MD         
Gesundheit Nord gGmbH, Klinikum Links der Weser gGmbH Recruiting
Bremen, Germany, 28277
Contact: Rainer Hambrecht, MD    +49-421-879 ext 1430   
Principal Investigator: Rainer Hambrecht, MD         
Sana Herzzentrum Cottbus GmbH Not yet recruiting
Cottbus, Germany, 03048
Contact: Jürgen Krülls-München, MD    +49-355-46 ext 2576   
Principal Investigator: Jürgen Krülls-Münch, MD         
Universitätsklinikum Düsseldorf Not yet recruiting
Düsseldorf, Germany, 40225
Contact: Malte Kelm, MD    +49-211-811 ext 8801   
Principal Investigator: Malte Kelm, MD         
Universitätsklinikum Erlangen Not yet recruiting
Erlangen, Germany, 91054
Contact: Christian Schlundt, MD    +49-9131-853 ext 5000   
Principal Investigator: Christian Schlundt, MD         
Universitäts-Herzzentrum Freiburg / Bad Krozingen Recruiting
Freiburg, Germany, 79106
Contact: Matthias Siepe, MD    +49-761-2702 ext 4010   
Principal Investigator: Matthias Siepe, MD         
Universitätsklinikum Gießen Recruiting
Gießen, Germany, 35392
Contact: Andreas Böning, MD    +49-641-985 ext 44300   
Principal Investigator: Andreas Böning, MD         
Universitätsmedizin Göttingen Recruiting
Göttingen, Germany, 37075
Contact: Bernd Danner, MD    +49-551-39 ext 6061   
Principal Investigator: Bernd Danner, MD         
Universitätsklinikum Schleswig-Holstein, Campus Kiel Recruiting
Kiel, Germany, 24105
Contact: Tim Attmann, MD    +49-431-597 ext 4465   
Principal Investigator: Tim Attmann, MD         
Herzzentrum Leipzig GmbH Not yet recruiting
Leipzig, Germany, 04289
Contact: Martin Misfeld, MD         
Principal Investigator: Martin Misfeld, MD         
Klinikum Ludwigshafen Recruiting
Ludwigshafen, Germany, 67063
Contact: Uwe Zeymer, MD    +49-621-503 ext 2941   
Principal Investigator: Uwe Zeymer, MD         
Universitätsklinikum Schleswig-Holstein, Campus Lübeck Recruiting
Lübeck, Germany, 23538
Contact: Michael Reppel, MD    +49-451-500 ext 2500   
Principal Investigator: Michael Reppel, MD         
Krankenhaus der Barmherzigen Brüder Trier Not yet recruiting
Trier, Germany, 54292
Contact: Ivar Friedrich, MD    +49-651-208 ext 2751   
Principal Investigator: Ivar Friedrich, MD         
Sponsors and Collaborators
Deutsches Herzzentrum Muenchen
Principal Investigator: Heribert Schunkert, MD Deutsches Herzzentrum Munich Germany
  More Information

No publications provided

Responsible Party: Deutsches Herzzentrum Muenchen Identifier: NCT01755520     History of Changes
Other Study ID Numbers: GE IDE No. D00112, 2012-003630-16
Study First Received: December 19, 2012
Last Updated: May 7, 2014
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Deutsches Herzzentrum Muenchen:
antiplatelet drug,

Additional relevant MeSH terms:
Acute Coronary Syndrome
Angina, Stable
Angina Pectoris
Cardiovascular Diseases
Chest Pain
Heart Diseases
Myocardial Ischemia
Signs and Symptoms
Vascular Diseases
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs processed this record on October 22, 2014